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Abstract
Background: We studied the pharmacology of l-methamphetamine, the less abused isomer, when
used as a nasal decongestant.
Methods: 12 subjects self-administered l-methamphetamine from a nonprescription inhaler at the
recommended dose (16 inhalations over 6 hours) then at 2 and 4 (32 and 64 inhalations) times this
dose. In a separate session intravenous phenylephrine (200 μg) and l-methamphetamine (5 mg)
were given to define alpha agonist pharmacology and bioavailability. Physiological, cardiovascular,
pharmacokinetic, and subjective effects were measured.
Results: Plasma l-methamphetamine levels were often below the level of quantification so
bioavailability was estimated by comparing urinary excretion of the intravenous and inhaled doses,
yielding delivered dose estimates of 74.0 ± 56.1, 124.7 ± 106.6, and 268.1 ± 220.5 μg for ascending
exposures (mean 4.2 ± 3.3 μg/inhalation). Physiological changes were minimal and not dose-
dependent. Small decreases in stroke volume and cardiac output suggesting mild cardiodepression
were seen.
Conclusion: Inhaled l-methamphetamine delivered from a non-prescription product produced
minimal effects but may be a cardiodepressant.
Background
There are two enantiomers of methamphetamine: dextro-
rotatory (d) methamphetamine and levorotatory (l)
methamphetamine. The d-isomer is commonly abused
and is available by prescription (DEA Schedule II), but
unknown to most physicians the l-isomer is sold over-the-
counter and is the active ingredient of the Vicks® Vapor
Inhaler (spelled levmetamfetamine by the manufacturer,
Procter & Gamble, Cincinnati, OH) [1,2]. Each Vicks
inhaler contains about 50 mg of l-methamphetamine,
and earlier estimates suggested delivered daily doses
between 1.9 to 7.2 mg of drug when used as directed [3].
The over-the-counter (OTC) vasoconstrictor nasal decon-
gestant phenylpropanolamine (PPA) was associated with
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that led to it being voluntarily withdrawn from the market
[4]. Ephedra, another component of OTC nasal decon-
gestants may also increase the risk of cardiovascular
adverse events [5]. Methamphetamine is a sympathomi-
metic vasoconstrictor that increases blood pressure and
myocardial oxygen consumption [6].
Despite the widespread use of OTC nasal decongestants,
there is surprisingly little published data on their pharma-
cologic effects. Thus, physicians may encounter patients
using l-methamphetamine but have little data on risks
and drug exposure. To date, there are no published data
on the pharmacology of intranasal l-methamphetamine.
The complications of OTC decongestants, although
severe, are exceedingly rare. Because adverse events of
these drugs are uncommon, observational studies are
unlikely to delineate mechanisms of action or toxicity.
Measures that assess cardiovascular, and pharmacokinetic
variables could assist in predicting risk and defining
mechanisms of action.
The effects of l-methamphetamine on cardiac function are
not yet defined. In this study we used impedance cardiog-
raphy to measure the effects of methamphetamine-
induced vasoconstriction on vascular resistance and car-
diac work. Because people using the inhaler are likely to
exercise (indeed one Olympic athlete lost a medal due to
Vicks inhaler use before his race) [7], interactions between
exercise and intranasal methamphetamine were assessed.
Understanding the effects of intranasal l-methampheta-
mine contained in the Vicks® Inhaler is important due to
the associated cardiovascular risks of other OTC nasal
decongestants. In addition, establishing the relative and
absolute bioavailability of l-methamphetamine in the
Vicks® Inhaler would aid in a further assessment of risk. In
this study, we examined the pharmacokinetic, cardiovas-
cular, and subjective effects of l-methamphetamine.
Doses were delivered using an easily available non-pre-
scription product – the Vicks® Vapor Inhaler.
Methods
Subject selection
Twelve subjects with a mean age of 38 (range 28 to 51
years old) participated in the study. Subjects were
recruited through advertisements, and were included if
they were normotensive, between 18 to 65 years, had a
normal physical examination, EKG, blood and urine
chemistries and had no nasal pathology that might alter
the absorption of l-methamphetamine.
Subjects were excluded if they had used nasal decongest-
ants within the last three months, were dependent on any
drugs other than caffeine or nicotine or had structural
abnormalities of the heart seen during a preliminary stress
echocardiogram. Women were required to have a negative
serum pregnancy test (Unilab, San Jose, California) before
each session. Subjects were not dependent on metham-
phetamine, alcohol or other illicit drugs using DSM-IV-R
criteria.
Because the Vicks® Inhaler is an OTC product, prior expe-
rience with methamphetamine was not necessary.
Informed consent was obtained and subjects were paid for
their participation. The study was approved by the UCSF
IRB.
Study design
Inhaled l-methamphetamine was self administered from
the commercially available Vick's® Inhaler using a 3 ses-
sion, ascending dose, open-label study design with ses-
sions separated by at least 1 week. Dosing was starting at
the manufacturer's recommended dose of 2 inhalations
per nostril every 2 hours. Within each session 4 dosing
periods occurred with periods separated by 2 hours; all
dosing within a session occurred over 8 hours. In the first
session subjects received 4 inhalations per period. Thus,
over 8 hours a total of 16 inhalations were given. In the
second and third sessions, the inhaler was administered
with the same 2 hour dose period but at 2 and 4 times the
recommended dose. In these sessions a total of 32 and 64
inhalations were given. Inactive ingredients in the Vicks
inhaler include bornyl acetate, camphor, lavender oil,
menthol and methyl salicylate. Subjects were admitted as
inpatients to the UCSF General Clinical Research Center
(GCRC) for approximately 36 hours.
Following administration of 3 ascending dose inhala-
tions, a fourth session was conducted to contrast the
effects of a prototypic alpha agonist phenylephrine, (Gen-
sia Sicor Pharmaceuticals, Irvine, CA) with those pro-
duced by inhaled methamphetamine and to administer a
parenteral dose of l-methamphetamine that would allow
determination of absolute bioavailability. A similar phe-
nylephrine challenge procedure has been safely used to
measure hemodynamic response in hypertensive patients
maintained off all antihypertensive medication for 2
weeks [8]. The phenylephrine response test was per-
formed by giving an intravenous phenylephrine bolus
dose of 100 μg. If the initial dose did not produce a 15
mm rise in systolic blood pressure within 15 minutes, a
second 200 μg dose was given at 30 minutes. Two hours
after the last phenylephrine dose, a slow (over 15 min-
utes) intravenous infusion of 5 mg of l-methampheta-
mine was administered to establish absolute
bioavailability. The l-methamphetamine was prepared
from the free base obtained from Sigma (St. Louis, MO)
under FDA IND 58,189. We had planned to quantify rel-
ative bioavailability by extracting and quantifying the
residual l-methamphetamine content from the inhalers.Page 2 of 9
(page number not for citation purposes)
BMC Clinical Pharmacology 2008, 8:4 http://www.biomedcentral.com/1472-6904/8/4However, the amount of l-methamphetamine in new
inhalers was highly variable (between 50 and 75 mg) and,
given the small delivered doses, we were not able to
obtain sufficiently accurate inhaler weights before and
after dosing to allow estimation of delivered doses.
Subjects were requested to abstain from both nicotine and
caffeine for approximately 12 hours before each dosing
and from alcohol for 48 hours prior to dosing. Subjects
were excluded from participation if they had a positive
qualitative urine test for abused drugs prior to dosing or
reported use of nicotine, caffeine or alcohol with the
above windows; no subjects were excluded for positive
qualitative urinalysis or caffeine, nicotine or alcohol use
within specified time limits. No caffeine was allowed until
stress echocardiograms were completed. No smoking was
permitted during the hospital stay; nicotine patches were
offered to all smokers. Vicks® Inhalers from a single batch
were used for each subject; all inhalers were purchased
from a single pharmacy.
Measures
Physiological measures
Blood pressure, heart rate, skin and core temperature, and
respiratory rate were measured using a non-invasive auto-
matic device (Escort II 300 Patient Monitor, Medical Data
Electronics, Arleta, Calif.) at 15 minutes before and 5, 15,
30 and 60 minutes within each period; and 2, 4, 8, 18, 24,
and 30 hours after the last period to assess safety. For Ses-
sion 4, before and after intravenous phenylephrine and l-
methamphetamine, vital signs were measured at 5-minute
intervals until they returned to baseline, then hourly for 8
hours, and then at 8-hour intervals until discharge.
Echocardiography and stress-echocardiograph
2D echo-Doppler examination was performed at the time
of enrollment to ensure normal cardiac structure and
function. To determine if l-methamphetamine produces
alterations in myocardial contractility with changes in vas-
cular resistance, a treadmill stress echocardiogram was
performed 15 minutes following the last period, except
after the methamphetamine infusion (session 4) where
the echo was done at 30 minutes. Subjects exercised to
general fatigue or until asked to stop. Stress ECG results
were defined as abnormal if there was ≥ 1.0-mm ST-seg-
ment depression measured at 80 ms after the J point in 2
contiguous leads during peak stress or immediately after
recovery.
Stress echocardiographic measurements were made at
baseline and 50%, 70%, and 85% of maximal heart rate.
The cardiovascular variables measured by stress echocar-
diography included systolic blood pressure, heart rate,
cardiac output, stroke volume, ejection fraction, systolic
wall stress, septal wall thickness, posterior wall thickness,
and left-ventricular internal diameter. Measurements
obtained approximately 15 minutes before exercise, and
immediately following exercise (85% of maximal heart
rate) were used in final analyses. Echocardiographic data
was analyzed offline (ProSolv CardioVascular Analyzer
with DICOM software).
Impedance cardiography
Impedance cardiographic measures of stroke volume and
ejection times were obtained before and at 15 minutes
and 2 hours within each period. Blood pressure and heart
rate were simultaneously obtained. From these variables,
systemic vascular resistance, left cardiac work, left ven-
tricular ejection time, and cardiac output were determined
using a dedicated commercially available system (Cardio-
dynamics) consisting of a personal computer with cus-
tomized data processing software, a transmitting unit with
four pairs of electrodes for analyses of the thoracic imped-
ance field.
Biological samples
Blood samples
For Sessions 1 to 3, 5-ml plasma samples for metham-
phetamine and metabolites were obtained 15 minutes
after inhalations (theoretical peak) and 5 minutes before
the next series of inhalations (theoretical trough), and
then 4, 8, 18, 24, and 30 hours after the last inhaled dose.
For Session 4, samples were obtained before and at 30
minutes, 1, 2, 4, 8, 18, 24, and 30 hours after metham-
phetamine. Samples were placed on ice immediately after
collection. Samples were obtained through an in-dwelling
venous catheter using sterile technique.
Urine samples
All urine was collected for the time from admission to just
prior to dosing and from 0–12 hours, 12–24 hours, and
24–36 hours after the beginning of dosing.
Assays
Plasma and urine l-methamphetamine concentrations
were determined according to a previously described gas
chromatography-mass spectrometry method [9].
Subjective measures
Visual Analog Scales were administered (Sessions 1 to 3)
15 minutes before the first period, at 5 and 30 minutes
within each period, and then 4, 8, 18, and 30 hours after
the last l-methamphetamine dose. In Session 4, tests were
administered 15 minutes before the phenylephrine dose
and then 0.5, 1.5, 4, 8, 18, and 30 hours after the first phe-
nylephrine dose. Items included Visual Analog Scale rat-
ings of "any drug effect," "good drug effect," "bad drug
effect," "nasal stuffiness," "nasal dryness," "headache,"
and "dizziness." Visual analog ratings were performed byPage 3 of 9
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line with 0 defined as "none" and 100 as the "most ever."
Statistical analysis
Group comparisons with PC-SAS's general linear model
procedure (SAS Institute Inc., Release 6.04 Edition, Cary,
N.C., 1990) and with multifactor repeated-measures anal-
ysis of variance were done with SAS (UNIX) or Super
ANOVA (Macintosh) software applications. Physiologic
data were transformed to change scores (post-treatment
minus pre) and analyzed by repeated measures analysis of
variance (ANOVA). Each session had 4 dosing periods.
Within each period the mean value of the identical time
points were calculated and used in the analysis. After a sig-
nificant F-test, pair-wise comparisons were performed
using the least squares means analysis. Effects were con-
sidered statistically significant at p ≤ 0.05. Data is pre-
sented as mean (SD).
Results
Methamphetamine concentrations
Plasma methamphetamine and amphetamine concentra-
tions were often below the limit of quantification (< 5 ng/
ml). Thus, absolute bioavailability and pharmacokinetic
variables could not be calculated. Measurable quantities
were excreted in the urine with maximum levels at the
highest dose (4× the recommended dose), showing a dose
response to inhalations. Peak amounts excreted in urine
occurred between 12–24 hours and then decreased signif-
icantly during the 24–36 hour collection (Figure 1).
We estimated the dose delivered by comparing urinary
excretion from the three inhalation conditions with the iv
condition. Total methamphetamine excretion (0–36
hours) was 40.7 (30.9) μg, 68.6 (58.6) μg, and 147.4
(121.2) μg for the 16, 32 and 64 inhalation conditions. It
was 2749.5 (499.6) μg following the 5 mg IV dose.
Assuming similar distribution and elimination of inhaled
and intravenous doses, estimated delivered nasal doses
for each session are 74.0 (56.1) μg, 124.7 (106.6) μg, and
268.1 (220.5) μg, respectively. The estimated delivery of a
single inhalation is approximately 4.2 (3.3) μg per inhala-
tion (range 0.8–14.3 μg/inhalation). Following inhala-
tions approximately 4% of the dose was excreted as l-
amphetamine (corrected for difference in molecular
weight); after intravenous dosing approximately 3% of
the dose was excreted as l-amphetamine.
Physiological measures
Most physiological variables did not change in a clear
dose-dependent manner. For example, systolic blood
pressure increased by 11.8 (16.2) and 12.3 (20.5) mmHg
(p = 0.02) in the 16 and 32 but fell by 1.2 (16) mmHg 64
inhalation conditions. Mean peak diastolic blood pres-
sure increased by 7 to 9 mmHg (p = 0.04) with no differ-
ence between doses. Across time, core temperature
increased by ~0.1°C in the 16 and 32 inhalation condi-
tions and decreased by ~0.1°C in the 64 inhalation con-
dition (p = 0.02). In the 64-inhalation condition
respiratory rate increased by 0.4 (1.68) (p = 0.02) breaths
per minute; no hyperthermia or respiratory distress was
seen in any condition. Peak respiratory rate increased by a
clinically insignificant 3 (2.5) breaths per minute in the
32-inhalation condition (p = 0.03). No significant
increases in heart rate were seen.
The intravenous methamphetamine dose did not alter
cardiovascular parameters – mean (SD) peak responses
were 2.9 (9.3) mmHg, 7.4 (12.5) mmHg, and 0.42 (4.4)
breaths/min in systolic and diastolic blood pressure, and
respiratory rate, respectively. In contrast to the results seen
in hypertensives, the phenylephrine doses (100 and 200
μg) produced no significant changes in blood pressure or
heart rate (Table 1). Interestingly, the 16 and 32 inhala-
tion conditions produced substantially more robust
effects on systolic blood pressure than the much larger
intravenous l-methamphetamine and phenylephrine
doses. All three inhalation conditions increased diastolic
blood pressure more than phenylephrine or intravenous l-
methamphetamine. Mean peak changes in physiological
variables are shown in Table 1.
Stress echocardiography
Intranasal l-methamphetamine did not alter the effect of
exercise on most cardiovascular measures. Exercise pro-
duced expected increases in cardiac output (p < 0.001),
ejection fraction (p < 0.001), heart rate (p < 0.001), systo-
lic wall stress (p = 0.002), and systolic blood pressure (p
≤ 0.001) and expected decreases in end-systolic left ven-
tricular internal diameter (p = 0.01). The cardiac response
to exercise was not affected by any inhaler dose level
except for septal wall thickeness (SWT), which increased
significantly only after the highest inhaler dose. This dif-
ference is most likely due to a single outlier. Echocardio-
graphic measurements are shown in Table 2.
Impedance cardiography
Significant differences were seen in a few cardiovascular
parameters at 15 minutes post dose. Inhaled l-metham-
phetamine decreased stroke volume by 3.9 to 6 mls/beat
(p = 0.01). Heart rate fell slightly by ~1 to 2 beats/per
minute. These small decreases in heart rate and stroke vol-
ume decreased cardiac output (CO) by ~0.5 l/min (p =
0.02). Systemic vascular resistance (SVR) increased in all
conditions by 106 to 137 dynes*sec*cm5 (1190
dynes*sec*cm5, 1259 dynes*sec*cm5, and 1278
dynes*sec*cm5 for 16, 32 and 64 inhaler doses, p =
0.004). However, this was a small absolute increase of less
than 10%. The increase in SVR is probably compensatingPage 4 of 9
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increase in blood pressure.
At two hours post-dose, many parameters were signifi-
cantly different from pre-dose conditions. In response to
l-methamphetamine, stroke volume remained 1.6 to 6.2
mls/beat below baseline (p = 0.02). Heart rate increased
by 4 to 5 beats/min (p = 0.003). Therefore, cardiac output
returned to approximately pre-dose values. Diastolic
blood pressure increased slightly by ~2 mmHg (p = 0.01).
A decrease of ~12 ms occurred in left ventricular ejection
time possibly resulting from the increase in heart rate. No
significant differences were found between conditions;
parameters are shown in Table 3. These results suggest
that l-methamphetamine has mild cardiodepressant
actions that initiate compensatory increases in heart rate
and systemic vascular resistance.
Subjective ratings
The subjective effects of inhaled l-methamphetamine
were modest. In all three inhaler conditions VAS peak (p
< 0.01) and overall (p = 0.001) ratings of "Any Drug Effect
increased, indicating that subjects noted a drug effect.
However, other ratings were inconsistent. VAS "Bad Drug
Effect," (p = 0.01) and "Dizziness" (p = 0.002) both sig-
nificantly increased across time with no significant differ-
ences between inhaler conditions but peak effects were
trivial and non-significant. The 64 inhalation condition
increased peak "Good Drug Effect" (p = 0.001) but only to
9.7 (13.0) on a 0–100 VAS scale. The 64 inhalation con-
dition increased VAS "headache" (p = 0.01) but again the
effect was modest [12.7 (17.0)]. Interestingly, the
parenteral phenylephrine and l-methamphetamine pro-
duced less subjective effects than the inhaled l-metham-
phetamine doses. Mean peak changes are shown in Table
4.
Discussion
l-Methamphetamine delivered through the Vicks® Inhaler
was well tolerated and produced minimal pharmacody-
namic effects, even at 4 times the maximum recom-
mended dose. Dose dependent but small increases in
systolic and diastolic blood pressure were seen. Imped-
ance cardiography results suggest that l-methampheta-
mine may actually depress cardiac function. There were
no effects of increasing l-methamphetamine dose on
stress echocardiography. Small increases in visual analog
"Good Drug Effect" were seen (from a mean of 5.8 to 9.7)
Methamphetamine and amphetamine concentrations excreted in the urine from 0–12, 12–24, and 24–36 hoursFigure 1
Methamphetamine and amphetamine concentrations excreted in the urine from 0–12, 12–24, and 24–36 hours. Values are 
means (SE). N = 11.
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amount in 12-hour urine collections
(mean + SE, n=11)
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Drug Effect," and "Dizziness" were also seen, suggesting a
low abuse liability in these non-drug using subjects.
Delivered doses from the inhaler are small and produce
correspondingly low plasma concentrations. Using an in-
vitro system, data available in the PDR and the Federal
Register suggests that [3,10], adults who inhale twice in
each nostril every two hours may expect a total inhaled
dose of 1.9 – 7.2 mg l-methamphetamine in a 24-hour
period, or 40 μg to 150 μg per 800 mls of air. However,
published source data are not cited and none could be
found after an extensive literature search. Using similar
dosing assumptions to the PDR we estimate that about 0.2
mg per 24 hours [4.2 (3.3) μg/inhalation] is delivered.
Therefore, our estimate is 10-fold less, probably due to
differences in the technique used to deliver inhaled dose.
Our estimate is based on the renal excretion of l-metham-
phetamine following controlled dosing in humans, which
may have caused considerable variability in our estimates.
Heavy use of the inhaler can produce substantial urinary
methamphetamine concentrations, some greater than
2000 ng/ml with concentrations up to 6000 ng/ml
reported [11]. Poklis (1995) treated 6 subjects either
hourly for 3 days or every 2 hours for 5 days while awake.
Use of the inhaler every 2 hours did not produce positive
urine tests but when administered hourly two subjects
had urinary concentrations of 1530 and 1560 ng/ml [12].
The small changes seen on most cardiovascular measures
appear to be of little clinical significance. Peak increases in
systolic blood pressure of approximately 12 mmHg did
occur in some cases in the 16 and 32 inhaler condition. In
the 64-inhalation condition systolic blood pressure fell,
suggesting a biphasic cardiovascular response to l-meth-
amphetamine. Morgan's report (1979) that the cardiovas-
cular system is more affected by l-amphetamine than d-
amphetamine may lead one to expect a similar or greater
cardiovascular response from the l-methamphetamine
contained in the Vicks® inhaler [13]. However, a 20% fall
in mean arterial pressure was seen after 1 mg/kg l-meth-
amphetamine in Sprague-Dawley rats [14]. This was
Table 1: Peak Changes in Physiological Variables in Response to Inhaled l-Methamphetamine, IV phenylephrine and IV l-
methamphetamine. 
Measure 16 Inhalations 32 Inhalations 64 Inhalations PE1 PE2 IV l-Meth Overall P-Value
Systolic Blood Pressure (mmHg) 11.8 (16.2)‡§||** 12.3 (20.5)‡§||** - 1.2 (16.0) 0.9 (10.1) 1.4 (9.8) 2.9 (9.3) 0.03
Diastolic Blood Pressure (mmHg) 8.7 (8.9)||** 6.6 (9.9)|| 9.0 (12.4)||** 1.9 (8.3) -2 (10.2) 7.4 (12.5)|| 0.04
Heart Rate (beats/min) 1.3 (12.3) 4.2 (19.2) 2.3 (14.3) 2.8 (9.7) -4.2 (7.9) - 0.33 (8.4) 0.62
Respiratory Rate (breaths/min) 0.17 (4.3) 3 (2.5)*§||** 2.4 (3.5)§|| - 1.9 (4.8) -1.5 (3.3) 0.42 (4.4) 0.003
Core Temperature (°C) 0.13 (0.8) - 0.32 (0.9) 0.21 (0.9) - 0.19(0.6) 0.08 (0.4) 0.09 (0.2) 0.41
Data presented as mean (SD).
PE1 = phenylephrine dose 1; PE2 = phenylephrine dose 2; IV l -Meth = IV l-methamphetamine
* = significantly greater than 16 inhalations
† = significantly greater than 32 inhalations
‡ = significantly greater than 64 inhalations
§ = significantly greater than PE1
|| = significantly greater than PE2
¶ significantly greater than IV l-methamphetamine
** = significantly greater than baseline
Table 2: Change in Cardiovascular Variables in Response to Exercise After Vicks Inhalation and IV l-Methamphetamine As Measured 
by Stress Echocardiography. Data presented as mean (SD).
Measure 16 Inhalations 32 Inhalations 64 Inhalations IV l-Meth Overall P-Value (time) Overall P-Value (dose)
Cardiac Output (l/min) 3.1 (2.0) 2.4 (2.2) 2.5 (2.5) 3.8 (2.3) < 0.001 0.10
Heart Rate (beats/min) 73.5 (26.7 66.3 (21.5) 64.5 (22.9) 76.9 (16.8) < 0.001 0.17
Systolic Blood Pressure (mmHg) 41.3 (18.7) 41.6 (42.6) 52.0 (13.9) 57.6 (11.6) < 0.001 0.35
Stroke Volume (ml) 3.3 (13.2) 2.5 (13.4) 2.1 (13.9) -0.02 (7.3) 0.41 0.90
LV Internal Diameter (cm) -2.6 (2.9) -2.1 (3.5) -1.8 (4.1) -2.0 (4.6) 0.01 0.96
Ejection Fraction (%) 8.9 (5.8) 7.8 (7.6) 6.3 (6.4) 9.9 (6.5) < 0.001 0.62
Systolic Wall Stress(kdynes/cm2) 64.5 (62.8) 51.7 (61.6) 41.7 (79.3) 81.7 (90.6) 0.002 0.42
Posterior Wall Thickness (cm) - 0.58 (1.4) 0.67 (1.3) 0.25 (0.97) 0.08 (1.5) 0.49 0.20
Septal Wall Thickness (mm) 0.08 (0.79) 0.08 (1.5) 2.0 (3.1) 0.25 (0.97) 0.05 0.04
Responses are post-exercise minus pre; wall thicknesses measurements are end-systolic
LV = Left Ventricular
p-values are based on overall p-values across time and dose.Page 6 of 9
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ance and a 40% decrease in cerebral blood flow. d-Meth-
amphetamine is usually a potent sympathomimetic alpha
agonist and vasoconstrictor where systolic and diastolic
blood pressure increase significantly with slight decreases
in heart rate consistent with a baroreceptor response
[6,15-17]. In contrast, our studies showed that these
effects did not occur in response to inhaled or intravenous
l-methamphetamine [16].
The small declines in stroke volume and cardiac output at
15 minutes within each period suggest that l-metham-
Table 3: Change in Cardiovascular Variables in Response to Inhaler Condition and IV l-Methamphetamine as Measured by Impedance 
Cardiography.
Measure 16 Inhalations 32 Inhalations 64 Inhalations IV l-Meth Overall P-Value (time) Overall P-Value (dose)
Cardiac Output (l/min)
15 minutes -0.53 (0.66) -0.46 (1.3) -0.56 (0.52) -0.01 (0.54) 0.02 0.67
2 Hours 0.0 (0.67) 0.05 (1.6) 0.31 (0.77) 0.28 (1.0) 0.32
Heart Rate (beats/min)
15 Minutes -2.6 (4.9) -2.1 (5.8) -1.7 (5.9) 1.0 (5.8) 0.38 0.60
2 Hours 4.3 (6.0) 5.4 (11.3) 4.3 (7.7) 6.1 (9.5) 0.003
Systolic Blood Pressure (mmHg)
15 Minutes 1.0 (12.5) -1.2 (6.6) -3.0 (6.4) 4.8 (9.0) 0.76 0.09
2 Hours 1.8 (7.9) -0.17 (7.0) 3.1 (6.9) 5.9 (6.9) 0.06
Diastolic Blood Pressure (mmHg)
15 Minutes 0.50 (7.5) 1.4 (6.7) 1.2 (6.4) 4.3 (8.8) 0.09 0.23
2 Hours 2.2 (4.2) 2.6 (6.5) 1.2 (4.9) 6.5 (8.1) 0.007
Stroke Volume
15 Minutes -3.9 (7.3) -4.9 (16.0) -6.0 (6.4) -1.0 (5.4) 0.008 0.66
2 Hours -5.4 (6.6) -6.2 (17.5) -1.6 (7.8) -0.67 (6.4) 0.02
Systemic Vascular Resistance 
(dynes*sec*cm5)
15 Minutes 106.0 (168.9) 137.1 (388.5) 129.1 (169.5) 48.8 (112.7) 0.004 0.89
2 Hours 47.2 (140.2) 72.0 (441.7) -10.2 (204.0) 12.3 (127.2) 0.36
Left CardiacWork
15 Minutes -0.51 (1.0) -0.48 (1.6) -0.59 (0.64) 0.44 (0.93) 0.21 0.12
2 Hours 0.22 (0.91) 0.23 (2.1) 0.53 (0.78) 1.1 (1.5) 0.03
LV Ejection Time
15 Minutes -0.75 (12.4) -4.8 (16.4) -12.4 (19.1) -0.25 (10.4) 0.19 0.54
2 Hours -11.8 (16.4) -12.1 (26.8) -11.8 (19.9) -6.4 (26.5) 0.005
Data presented as mean (SD).
IV-l-meth-IV l-methamphetamine; p-value (time)-compared to baseline vs. 15 minutes and 2 hours post-dose
Table 4: Peak Changes in VAS Subjective Variables in Response to Inhaled l-Methamphetamine, IV phenylephrine and IV l-
methamphetamine.
Measure 16 Inhalations 32 Inhalations 64 Inhalations PE1 PE2 IV l-Meth Overall P-Value
Any Drug Effect 9.0 (13.9)§||** 7.3 (10.5)§||** 9.8 (7.9)§||¶** 1.5 (2.1) 1.7 (2.4) 4.5 (8.6) 0.001
Bad Drug Effect 6.8 (13.7) 2.8 (4.6) 4.9 (5.0) 0.33 (0.9) 1.1 (0.79) 5.3 (10.7) 0.07
Dizziness 9.3 (14.0)§||¶** 6.5 (6.4)¶** 9.0 (13.5)§||¶** 1.5 (2.9) 0.92 (2.2) -0.67 (5.7) 0.004
Good Drug Effect 5.8 (13.0)||** 5.7 (10.5)** 9.7 (13.0)§||¶** 0.42 (2.9) 0.25 (1.5) 2.7 (4.7) 0.005
Headache 5.1 (18.1) 4.8 (5.1)|| 12.7 (17.0)§||¶** -0.08 (1.7) 1.8 (3.3) -3.8 (13.4) 0.02
Nasal Dryness 5.2 (16.2) 3.3 (9.6) 4.1 (9.9) -0.75 (2.1) -0.50 (1.7) -0.42 (2.7) 0.20
Nasal Stuffiness 1.1 (16.9) 2.8 (4.8) 1.4 (6.7) 0.50 (4.4) -1.6 (3.6) 0.42 (1.2) 0.88
Data presented as mean (SD).
PE1 = phenylephrine dose 1; PE2 = phenylephrine dose 2; IV l -Meth = IV l-methamphetamine
*= significantly greater than 16 inhalations
† = significantly greater than 32 inhalations
‡ = significantly greater than 64 inhalations
§ = significantly greater than PE1
|| = significantly greater than PE2
¶ significantly greater than IV l-methamphetamine
** = significantly greater than baselinePage 7 of 9
(page number not for citation purposes)
BMC Clinical Pharmacology 2008, 8:4 http://www.biomedcentral.com/1472-6904/8/4phetamine may have some cardiodepressant effects, simi-
lar to those seen by Abassi [14]. Heart rate did not change
significantly but SVR increased by ~10%, maintaining
blood pressure. All subjects in this study were young and
had normal cardiovascular function. For people with
compromised ventricular function the negative inotropic
effects of inhaled l-methamphetamine could become clin-
ically significant; to date no reports of heart failure associ-
ated with l-methamphetamine have been reported. In
contrast to the nasal decongestants removed from the
market the product containing l-methamphetamine mod-
estly increased blood pressure. However, the ~12 mmHg
maximal increases seen are unlikely to produce medical
complications in young, otherwise healthy people.
The response to exercise was not affected by l-metham-
phetamine. Even at 4 times the recommended dose, intra-
nasal l-methamphetamine did not alter the effects of
exercise. For instance, as measured by impedance cardiog-
raphy changes in cardiac output (0.5 l/min) and stroke
volume (5 mls) in the 32 and 64 inhalation conditions
were small. Athletes that may use this product would
unlikely have enhanced cardiovascular performance, even
at high doses.
Recently, we reported on isomeric differences between d-
and l methamphetamine in humans [16]. d-Methamphet-
amine produces larger and more sustained cardiovascular
and subjective effects than identical doses (0.5 mg/kg and
0.25 kg/kg i.v. over 1 minute) of l-methamphetamine,
suggesting that the enantiomers act through different
pharmacologic mechanisms. In this study, intranasal l-
methamphetamine generally did not produce clinically
significant cardiovascular effects. Small increases in visual
analog ratings of "Any Drug Effect" indicate that subjects
perceived effects and small increases in "Bad Drug Effect"
and "Dizziness" suggest non-drug users do not find inhal-
ing l-methamphetamine pleasurable. The 64-inhalation
condition produced a small (change score of ~6) increase
in "Good Drug Effect" suggesting a low potential for abuse
even though occurrences of inhaler abuse is reported in
the literature [1,18,19]. Larger doses of intravenous l-
methamphetamine are psychoactive and may have some
abuse potential in methamphetamine users [16].
Stroke is a serious but rare complication of nasal decon-
gestant use. The risk of stroke after phenylpropylalinine (a
related nasal decongestant now off the market) was great-
est in those just initiating use and may be related to the
development of tolerance with repeated use [4]. Metham-
phetamine is an indirectly acting sympathomimetic
amine that potentiates the presynaptic release and blocks
reuptake of catecholamine neurotransmitters (norepine-
phrine and dopamine), thus activating the sympathetic
nervous system [20-22]. However, sustained exposure to
high doses of methamphetamine results in depletion of
monoamine [22-25]. Infrequent users of the intranasal l-
methamphetamine (people with a cold) may have more
catecholamine stores compared to chronic methampheta-
mine abusers, and could have a greater pharmacodynamic
response to small doses of l-methamphetamine. Accord-
ing to Zhu et al. (2000) stroke is the most common cause
of sudden death in first time methamphetamine users
[26]. Our results suggest this adverse event should be
uncommon with inhaled l-methamphetamine.
There are several limitations to our study. The lack of a
placebo limits our ability to assess the importance of the
small increases in blood pressure seen. Similar diurnal
changes in blood pressure may have occurred without l-
methamphetamine. We only studied normotensive peo-
ple; results in hypertensives might differ. Normotensives
may be more resistant to alpha agonist stimuli; in this
study they had minimal responses to both intravenous l-
methamphetamine and phenylephrine. Hypertensives
might show more cardiovascular effects after a sympatho-
mimetic amine like l-methamphetamine, and possibly be
at greater risk for cardiovascular adverse events.
In summary, the low doses of inhaled l-methampheta-
mine delivered from the Vicks inhaler produced little car-
diovascular effects in healthy people, even when given in
amounts much larger than recommended. Over time,
changes in blood pressure and heart rate were clinically
insignificant. Significant peak increases in systolic blood
pressure did occur, however, a biphasic response was seen
since systolic blood pressure fell following the highest
inhaler dose. The clinically significance of this finding
requires further study. Stroke volume and cardiac output
decreased but systemic vascular resistance increased sug-
gesting a compensatory mechanism to maintain blood
pressure. Overall, the results indicate that inhaled l-meth-
amphetamine at these doses appears to be a slight cardio-
depressant. A straightforward dose-dependence did not
occur on most measures. The mild subjective changes sug-
gest that l-methamphetamine, at least when delivered
from a widely available non-prescription product, is well
tolerated and has a low potential for abuse.
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